These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 29061943)

  • 1. Comparative Aspects of BRAF Mutations in Canine Cancers.
    Mochizuki H; Breen M
    Vet Sci; 2015 Aug; 2(3):231-245. PubMed ID: 29061943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying the ErbB/MAPK Signaling Cascade as a Therapeutic Target in Canine Bladder Cancer.
    Cronise KE; Hernandez BG; Gustafson DL; Duval DL
    Mol Pharmacol; 2019 Jul; 96(1):36-46. PubMed ID: 31048548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence analysis of RAS and RAF mutation hot spots in canine carcinoma.
    Mochizuki H; Breen M
    Vet Comp Oncol; 2017 Dec; 15(4):1598-1605. PubMed ID: 27714944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF Mutations in Canine Cancers.
    Mochizuki H; Kennedy K; Shapiro SG; Breen M
    PLoS One; 2015; 10(6):e0129534. PubMed ID: 26053201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption.
    Thomas R; Wiley CA; Droste EL; Robertson J; Inman BA; Breen M
    PLoS Genet; 2023 Apr; 19(4):e1010575. PubMed ID: 37079639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
    Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer--Evidence for a Relevant Model System and Urine-Based Diagnostic Test.
    Decker B; Parker HG; Dhawan D; Kwon EM; Karlins E; Davis BW; Ramos-Vara JA; Bonney PL; McNiel EA; Knapp DW; Ostrander EA
    Mol Cancer Res; 2015 Jun; 13(6):993-1002. PubMed ID: 25767210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IQGAP1 is an oncogenic target in canine melanoma.
    Lee BH; Neela PH; Kent MS; Zehnder AM
    PLoS One; 2017; 12(4):e0176370. PubMed ID: 28445541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives.
    Crispo F; Notarangelo T; Pietrafesa M; Lettini G; Storto G; Sgambato A; Maddalena F; Landriscina M
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31540406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.
    Jang S; Atkins MB
    Clin Pharmacol Ther; 2014 Jan; 95(1):24-31. PubMed ID: 24080641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma.
    Fowles JS; Denton CL; Gustafson DL
    Vet Comp Oncol; 2015 Sep; 13(3):288-304. PubMed ID: 23745794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma.
    Carlino MS; Long GV; Kefford RF; Rizos H
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):385-98. PubMed ID: 26358420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas.
    Penman CL; Faulkner C; Lowis SP; Kurian KM
    Front Oncol; 2015; 5():54. PubMed ID: 25785246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers.
    Kotani H; Adachi Y; Kitai H; Tomida S; Bando H; Faber AC; Yoshino T; Voon DC; Yano S; Ebi H
    Oncogene; 2018 Mar; 37(13):1775-1787. PubMed ID: 29348459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
    Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
    Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
    El-Nassan HB
    Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of BRAF-mutated advanced cutaneous melanoma.
    Trinh VA; You Y; Hwu WJ
    Chin Clin Oncol; 2014 Sep; 3(3):28. PubMed ID: 25841454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.
    Sánchez-Torres JM; Viteri S; Molina MA; Rosell R
    Transl Lung Cancer Res; 2013 Jun; 2(3):244-50. PubMed ID: 25806238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.